ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and financial results for the quarter ended June 30, 2014.
“We are pleased with the continued progress of the RX-3117, Supinoxin™ and Archexin® clinical development programs,” stated Rexahn’s Chief Executive Officer Peter D. Suzdak, PhD. “Positive data from these studies would be major milestones and will help direct the next steps for the Company.”
Help employers find you! Check out all the jobs and post your resume.
